WO2001097856A3 - An orphan nuclear receptor - Google Patents

An orphan nuclear receptor Download PDF

Info

Publication number
WO2001097856A3
WO2001097856A3 PCT/IB2001/001629 IB0101629W WO0197856A3 WO 2001097856 A3 WO2001097856 A3 WO 2001097856A3 IB 0101629 W IB0101629 W IB 0101629W WO 0197856 A3 WO0197856 A3 WO 0197856A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
methods
orphan nuclear
relates
nuclear receptor
Prior art date
Application number
PCT/IB2001/001629
Other languages
French (fr)
Other versions
WO2001097856A2 (en
Inventor
Steven A Kliewer
Stacey A Jones
Timothy M Willson
Original Assignee
Glaxo Group Ltd
Steven A Kliewer
Stacey A Jones
Timothy M Willson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Steven A Kliewer, Stacey A Jones, Timothy M Willson filed Critical Glaxo Group Ltd
Priority to AU2001284343A priority Critical patent/AU2001284343A1/en
Priority to JP2002503339A priority patent/JP2003535912A/en
Publication of WO2001097856A2 publication Critical patent/WO2001097856A2/en
Publication of WO2001097856A3 publication Critical patent/WO2001097856A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a novel human orphan nuclear receptor that binds to a cytochrome P-450 monooxygenase (CYP) promoter and that is activated by compounds that induce CYP gene expression. The invention further relates to nucleic acid sequences encoding such a receptor, to methods of making the receptor and to methods of using the receptor and nucleic acid sequences encoding same. The invention also relates to non-human animals transformed to express the human receptor and to methods of using such animals to screen compounds for drug interactions and toxicities.
PCT/IB2001/001629 2000-06-21 2001-06-21 An orphan nuclear receptor WO2001097856A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001284343A AU2001284343A1 (en) 2000-06-21 2001-06-21 An orphan nuclear receptor
JP2002503339A JP2003535912A (en) 2000-06-21 2001-06-21 Nuclear orphan receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59826700A 2000-06-21 2000-06-21
US09/598,267 2000-06-21

Publications (2)

Publication Number Publication Date
WO2001097856A2 WO2001097856A2 (en) 2001-12-27
WO2001097856A3 true WO2001097856A3 (en) 2003-01-23

Family

ID=24394885

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/001629 WO2001097856A2 (en) 2000-06-21 2001-06-21 An orphan nuclear receptor

Country Status (3)

Country Link
JP (1) JP2003535912A (en)
AU (1) AU2001284343A1 (en)
WO (1) WO2001097856A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238491B1 (en) 1998-03-27 2007-07-03 Smithkline Beecham Corporation Pregnane X receptor method
JP2007119359A (en) * 2005-10-25 2007-05-17 Fujifilm Corp Cancer inhibitor
JP2009120486A (en) * 2005-12-05 2009-06-04 Mitsubishi Pharma Corp New activator of orphan receptor in nucleus and application of the same
JP5061352B2 (en) * 2006-01-04 2012-10-31 国立大学法人 東京医科歯科大学 Liver disease therapeutic agent and liver function improving agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048915A1 (en) * 1998-03-27 1999-09-30 Glaxo Group Limited Orphan nuclear receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048915A1 (en) * 1998-03-27 1999-09-30 Glaxo Group Limited Orphan nuclear receptor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MOORE LINDA B ET AL: "St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 13, 20 June 2000 (2000-06-20), June 30, 2000, pages 7500 - 7502, XP002200518, ISSN: 0027-8424 *
PAOLINI MORENO ET AL: "Bile acid structure and selective modulation of murine hepatic cytochrome P450-linked enzymes.", HEPATOLOGY, vol. 30, no. 3, 1999, pages 730 - 739, XP008003770, ISSN: 0270-9139 *
PAOLINI MORENO ET AL: "Mechanism for the prevention of cholestasis involving cytochrome P4503A overexpression.", JOURNAL OF INVESTIGATIVE MEDICINE, vol. 48, no. 1, January 2000 (2000-01-01), pages 49 - 59, XP008003771, ISSN: 1081-5589 *

Also Published As

Publication number Publication date
AU2001284343A1 (en) 2002-01-02
JP2003535912A (en) 2003-12-02
WO2001097856A2 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
EA200702548A1 (en) Method of producing chlorohydrin from polyhydroxylated aliphatic hydrocarbon
WO2004087758A3 (en) Il 13 receptor alpha 2 antibody and methods of use
WO2006025979A3 (en) Modulators of nuclear receptors
WO2001036473A3 (en) Human g protein-coupled receptors
NZ623716A (en) Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2005109905A3 (en) Time-based graphical user interface for television program information
ZA200508390B (en) Compositions and methods for the therapy of inflammatory bowel disease
WO2001048015A3 (en) G protein-coupled receptors
WO2007114861A3 (en) Il-21 receptor antagonists
WO2001097856A3 (en) An orphan nuclear receptor
WO2005084208A3 (en) A novel class of sterol ligands and their uses in regulation of cholesterol and gene expression
MXPA02008239A (en) Human schizophrenia gene.
WO2005052152A8 (en) Dna participating in hydroxylation of macrolide compound
AU2003222535A8 (en) Compositions and methods for the modification of gene expression_using the superubiquitin promoter from pinus radiata
WO2001064876A3 (en) Human schizophrenia gene
WO2004096855A3 (en) Methods utilising g-protein coupled receptor 54
WO2004094654A3 (en) Transfection kinetics and structural promoters
WO2001068858A8 (en) Human g protein-coupled receptors
WO2001083553A3 (en) G protein-coupled receptors
PL1941269T3 (en) A method of screening a biological target for weak interactions using weak affinity chromatography
DK1444363T3 (en) Transfection kinetics and structural promoters
WO2001062924A3 (en) Human g protein-coupled receptors
南明宏 Xcode Tools
WO2003064465A3 (en) Prkag3 gene promoter and uses thereof
WO2001077175A3 (en) G protein-coupled receptors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 503339

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase